Newer clinically available antithrombotics and their antidotes

Journal of Interventional Cardiac Electrophysiology

Volumn 40, Issue 3, 2014, Pages 269-275

  Lévy, Samuel ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Antidotes; Apixaban; Dabigatran; New oral anticoagulants; Rivaroxaban

Indexed keywords

ANTIDOTE; ANTITHROMBIN; APIXABAN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; HEMOSTATIC AGENT; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; RIVAROXABAN; THIOPHENE DERIVATIVE;

ANALOGS AND DERIVATIVES; ANIMAL; BLOOD CLOTTING; DRUG EFFECTS; ELECTIVE SURGERY; HEMORRHAGE; HUMAN; STROKE; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTIDOTES; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION; ELECTIVE SURGICAL PROCEDURES; FACTOR XA INHIBITORS; HEMORRHAGE; HEMOSTATICS; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDONES; STROKE; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 84929998333     PISSN: 1383875X     EISSN: 15728595     Source Type: Journal    
DOI: 10.1007/s10840-014-9910-2     Document Type: Article

References (28)

1. Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., et al. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine, 361, 1139–1151.
2. Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., et al. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England Journal of Medicine, 365(10), 883–891.
3. Granger, C. B., Alexander, J. H., McMurray, J. J., Lopes, R. D., Hylek, E. M., Hanna, M., et al. (2011). Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 15(36), 981–992.
4. Hankey, G. J., & Eikelboom, J. W. (2011). Dabigatran etexilate: a new oral thrombin inhibitor. Circulation, 123, 1436–1450.
5. Fox, K. A., Piccini, J. P., Wojdyla, D., Becker, R. C., Halperin, J. L., Nessel, C. C., et al. (2011). Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. European Heart Journal, 32, 2387–2394.
6. Wallentin, L., Lopes, R. D., Hanna, M., Thomas, L., Hellkamp, A., Nepal, S., et al. (2013). Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation, 127, 2166–2176.
7. Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Hacke, W., Oldgren, J., et al. (2013). European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace, 15, 625–651.
8. Usman, M. H., Notaro, L. A., Patel, H., & Ezekowitz, M. D. (2008). New developments in anticoagulation for atrial fibrillation. Current Treat Options Cardiovascular Medicine, 10, 388–397.
9. Piccini, J. P., Lopes, R. D., & Mahaffey, K. W. (2010). Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. Current Opinion in Cardiology, 25, 312–320.
10. Schiele, F., van Ryn, J., Canada, K., Newsome, C., Sepulveda, E., Park, J., et al. (2013). A specific antidote for dabigatran: functional and structural characterization. Blood, 121, 3554–3562.
11. Millar, C. M., & Lane, D. A. (2013). Blocking direct inhibitor bleeding. Blood, 121, 3543–3544.
12. Van Ryn, J., Stangier, J., Haertter, S., Liesenfeld, K. H., Wienen, W., Feuring, M., et al. (2010). Dabigatran etexilate—novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thrombosis & Haemostasis, 103, 1116–1127.
13. Eerenberg, E. S., Kamphuisen, P. W., Sijpkens, M., Meijers, J. C., Buller, H. R., & Levi, M. (2011). Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate. A randomized, placebo-controlled, crossover study in healthy subjects. Circulation, 124, 1573–1579.
14. Marlu, R., Hodaj, E., Paris, A., Albaladejo, P., Cracowski, J. L., & Pernod, G. (2012). Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thrombosis & Haemostasis, 108, 217–224.
15. Makris, M., Van Veen, J. J., Tait, C. R., Mumford, A. D., & Laffan, M. (2013). British Committee for Standards in Hematology Guideline on the management of bleeding in patients on antithrombotic agents. British Journal of Haematology, 160, 35–46.
16. Pujadas-Mestres, L., Escolar, G., Arellano-Rodrigo, E., & Galán, A. M. (2013). Apixaban in the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. Drugs of Today (Barcelona, Spain), 49, 425–436.
17. Crowther, M. A., Ageno, W., Garcia, D., Wang, L., Witt, D. M., Clark, N. P., et al. (2009). Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Annals of Internal Medicine, 150, 293–300.
18. Lu, G., De Guzman, F. R., Hollenbach, S. J., Karbarz, M. J., Abe, K., Lee, G., et al. (2013). A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nature Medicine, 19, 446–451.
19. Sarode, R., Milling, T. J., Refaai, M. A., et al. (2013). Efficacy and safety of a 4-factor prothrombin Complex concentrate in patients on vitamin K antagonists presenting with major bleeding. A randomized, plasma-controlled, phase IIb study. Circulation, 128, 1234–1241.
20. Boehringer Ingelheim Pharmaceuticals. Study to evaluate the safety, pharmacokinetics and pharmacodynamics of BI 655075 administered alone or with dabigatran etexilate. http://clinicaltrials.gov/show/NCT01688830. Accessed 8 May 2013.
21. Portola Pharmaceuticals, 2013. PRT4445: FXa inhibitor antidote. http://www.portola.com/PRT4445-Fxa-Inhibitor-Antidote. Accessed 8 May 2013.
22. Portola Pharmaceuticals. Phase 2 healthy volunteer studies to evaluate the ability of PRT064445 to reverse the effects of several blood thinner drugs on laboratory tests. http://clinicaltrials.gov/show/NCT01758432. Accessed 8 May 2013.
23. Pfizer Press Release, Nov 1 2012. Portola, Bristol-Myers Squibb and Pfizer sign clinical collaboration agreement to study ELIQUIS® and Portola’s universal factor Xa inhibitor antidote PRT4445. http://press.pfizer.com/press-release/portola-bristol-myers-squibb-and-pfizer-sign-clinical-collaboration-agreement-study-el.
24. Janssen Press Release, Feb 5 2013. XARELTO® to be studied with factor Xa inhibitor antidote. http://www.janssenpharmaceuticalsinc.com/assets/P2_Antidote_Study_Press%20Release_Janssen_FINAL.pdf.
25. Janssen Research & Development, LLC. A study to assess the effects of 2 different prothrombin complex concentrates on the pharmacodynamics of rivaroxaban in healthy adult volunteers. http://clinicaltrials.gov/show/NCT01656330. Accessed 8 May 2013.
26. Pernod, G., Albaladejo, P., Godier, A., et al. (2013). Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP)-March 2013. Archives of Cardiovascular Diseases, 106, 382–393.
27. Holster, L., Hunfeld, N. G. M., Kuipers, E. J., Kruip, M. J. H. A., & Tjwa, E. T. T. L. (2013). On the treatment of new oral anticoagulant-associated gastrointestinal hemorrhage. Journal of Gastrointestinal and Liver Diseases, 22, 229–231.
28. Crowther, M. A., & Warkentin, T. E. (2009). Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. Journal of Thrombosis and Haemostasis, 7(Suppl 1), 107–110.